INTRODUCTION
High-dose chemoradiotherapy followed by autologous stem-cell transplantation (ASCT) has become standard practice for many hematologic malignancies, solid tumors and other nonmalignant disorders. 1 Toxicity and mortality associated with ASCT have been reduced thanks to several factors, principally the use of mobilized peripheral blood stem cells, administration of granulocyte colony-stimulating factor after progenitor cells infusion, and improvement of prophylactic antibiotic regimens. [2] [3] [4] Aside from these factors, outpatient parenteral antimicrobial treatment has been proven feasible and safe thanks to modern intravenous catheters and infusion devices (ie, portable intermittent infusion pump). 5, 6 These advances have led to the development of ASCT programs on an at-home basis, and several studies have demonstrated the safety of such programs. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The main advantages of at-home ASCT are the improvement in the quality of life of the patients and the reduction in the number of days during which patients have to be admitted to hospital, with a consequent reduction of costs, risk of nosocomial infections and pressure on available beds. These facts have prompted the extension of this procedure to the allogeneic setting. [21] [22] [23] [24] In this context, Svahn et al showed that at-home management of allogeneic transplants reduced the incidence of infections and improved survival with respect to a control group managed at the hospital. 21, 22 However, there are no studies making a similar comparison for autologous transplants, which represent more than 60% of the patients who undergo transplantation and, consequently, represent a significant workload for most transplant units. 25 Nevertheless, one of the most significant limitations of at-home ASCT is the frequent need for hospital readmission because of fever and infections related to neutropenia. [7] [8] [9] [10] [11] [12] [13] [14] [15] Against this background, we developed an at-home ASCT program in which ceftriaxone was administered from day ϩ1 after transplantation, with the hypothesis that this approach would reduce the rate of bacterial infections and the needforrehospitalization.Inthisreport,theresultsobtainedin50patients receiving an ASCT at home are compared with those observed in 50 matched patients who underwent conventional ASCT in the hospital.
PATIENTS AND METHODS

Patients and Requirements for At-Home ASCT
Between November 2000 and February 2005, 178 consecutive patients underwent ASCT for a hematologic malignancy at the Hematology Department of the Hospital Clinic of Barcelona (Barcelona, Spain). Eligibility for at-home ASCT included Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; travel time from home to the hospital less than 60 minutes; a caregiver available 24 hours a day, 7 days a week; and patient acceptance. The hospital clinic ethical committee approved the study, and all patients signed a written informed consent.
At-Home Unit
An at-home unit was organized to provide assistance to up to two patients simultaneously. This unit consists of three clinical nurses (C.G., A.H., and S.S.) available from 8:00 AM to 10:00 PM, in two shifts, 7 days a week, and a designated physician (F.F.-A.) available 8 hours per day, 5 days a week. Outside of these times, the hematologist on call at the hospital was in charge of providing medical assistance.
Home Care
All patients, except two who received oral busulfan at home, received high-dose chemotherapy and stem cell infusion at the hospital. The day after stem-cell infusion (day ϩ1), patients were discharged provided that they did not have fever or any other complication requiring treatment in the hospital. Thereafter, a nurse visited the patient once daily to check temperature, blood pressure, heart frequency, presence of mucositis, oral intake, central venous catheter status, and for administering intravenous (IV) medications. Blood samples were taken at home three times a week to check blood counts and chemical parameters.
Infection Prophylaxis and Supportive Therapy
During the aplasia period patients were managed in a protective reverse isolation (those in the in-hospital group in a single high-efficiency particulate air-filtered room). Anti-infectious prophylaxis was started the first day of conditioning (Table 1 ). This included ciprofloxacin 500 mg/12 hours orally (PO) until neutrophil recovery, fluconazole 50 mg/d PO until day ϩ30. In case of positive herpes simplex virus serology, acyclovir 800 mg/12 hours PO was administered until day ϩ30. Antibiotics were administered IV if WHO mucositis more than grade 2 was present. For Pneumocystis jiroveci prophylaxis, patients received aerosolized pentamidine 300 mg/28 days from day Ϫ7 until engraftment, followed by trimethoprim/sulfamethoxazole double strength, two times weekly, maintained for 6 months. Besides the afore-mentioned antibiotic prophylaxis, patients treated at home received ceftriaxone 1 g/d IV from day ϩ1 until the first day of febrile neutropenia or until first day of absolute neutrophil count higher than 1 ϫ 10 9 /L. Patients from both groups received granulocyte colony stimulating factor 5 g/kg/d IV from day ϩ7 until neutrophil count reached at least 1 ϫ 10 9 /L for two consecutive days. RBC and platelet transfusions were administered when hemoglobin concentration and platelet count were below 8 g/dL and 10 ϫ 10 9 /L, respectively. Mucositisrelated pain was treated with oral morphine in at-home patients, and with methadone IV or morphine IV perfusion in the in-hospital patients.
Empirical Antibiotic Regimen
In the at-home group, patients were instructed to go to the hospital in the case of temperature of 38°C or higher. After a chest x-ray and appropriate cultures, piperacillin and tazobactam 4.5 g/8 hours IV was started. In the absence of hemodynamic instability, pneumonia, or cardiac or respiratory distress, patients were discharged the same day to continue the antibiotic IV treatment through a portable intermittent infusion pump (Table 1) . Teicoplanin was added, 400 mg/12 hours IV two doses followed by 400 mg/d, if WHO mucositis grade 2 or higher, signs of infection at the catheter insertion, or positive blood cultures taken from the indwelling IV catheter for Coagulasenegative Staphylococci. If fever persisted more than 3 days, empirical amikacin 15 mg/kg/d IV was started. The same algorithm was used for the in-hospital group management of febrile neutropenia, but imipenem 500 mg/6 hours IV was administered as first-line antibiotic and vancomycin 15 mg/kg/12 hours IV was added under the same indications as with teicoplanin. Amphotericin B 0.7 to 1 mg/kg/d IV was started if fever persisted more than 5 days. Antibiotic treatment was maintained until the neutrophil count was superior to 1 ϫ 10 9 /L and patients were afebrile for at least 3 days with no infectious symptoms.
Criteria for Hospital Readmission in At-Home Group
Indications for readmission to the hospital were willingness of the patient or of the caregiver; uncontrolled nausea, vomiting or diarrhea; mucositis requiring total parenteral nutrition or IV morphics; hemodynamic instability, pneumonia, cardiac and/or respiratory distress. Discharge criteria to the outpatient unit from both at-home and in-hospital units were the same in both groups of patients: absolute neutrophil count higher than 1 ϫ 10 9 /L and to remain afebrile without antibiotic administration for a minimum of 48 hours.
Definitions
Engraftment. Granulocyte engraftment was defined as the first of 2 consecutive days with a neutrophil count of 0.5 ϫ 10 9 /L or higher, and platelet engraftment as the first of 2 consecutive days with an unsupported count of 20 ϫ 10 9 /L or higher. Fever. Febrile neutropenia was defined as a temperature of 38°C or higher in a patient with an absolute neutrophil count of less than 0.5 ϫ 10 9 /L. A new febrile episode was defined as the reappearance of temperature of 38°C or higher after an afebrile period of 5 consecutive days or longer, not related to transfusion or reaction to drug administration. Bacteremia was defined as the isolation of bacteria from a blood culture in the presence of fever with or without other symptoms and/or signs of infection. Coagulase-negative Staphylococci was considered as significant pathogen when isolated from at least two separate consecutive blood cultures. Imipenem (500 mg/6 hours IV)
Abbreviation: IV, intravenously.
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Administered using a portable intermittent infusion pump.
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Analysis of Charges
We included all charges generated, for each patient, from day ϩ1 until neutrophil count more than 1 ϫ 10 9 /L and patient was afebrile without antibiotic administration for a minimum of 48 hours. Six items were analyzed: at-home structure and hospital room, physician fees, nurse fees, pharmacy, transfusion, and laboratory.
Statistical Methods
Characteristics between groups were compared by using 2 test or Fisher's exact test (two tailed) for categoric variables and t test or the MannWhitney U nonparametric test for continuous variables. The level of significance was set at P Ͻ .05. All analyses were carried out using SPSS version 12 statistical software (SPSS Inc, Chicago, IL).
RESULTS
Patient Cohorts
One hundred seventy-eight patients received an ASCT during the study period, of which 128 (72%) were not included in the athome program due to ECOG performance status more than 2 (n ϭ 35; 27.3%), patient decision (n ϭ 45; 35.2%), geographic distance (n ϭ 32; 25%), no caregiver available (n ϭ 12; 9.4%), and previous ASCT (n ϭ 4; 3.1%). Fifty patients (28%) were eligible for at-home ASCT. The control-group patients were selected from the 89 patients with ECOG performance status 0 to 2 who were not allocated to the at-home program because of patient decision, geographic distance, or because there was no available caregiver. Control patients were individually matched to the at-home cases on a 1:1 ratio, taking into account all characteristics: age Ϯ 5 years, sex, diagnosis, stage of disease, conditioning, and source of stem cells (Table 2) .
Engraftment and Days to Transfer to the Outpatient Unit
Among the 50 patients of the at-home group, 45 cases (90%) were discharged the day after the infusion of progenitor cells. In five cases, discharge was delayed to the second (n ϭ 3) or third day (n ϭ 2) after stem-cell infusion because of transient toxicity. Days CSF after , unless otherwise noted. Abbreviations: ECOG, Eastern Cooperative Oncology Group; NS, not significant; CR, complete remission; PR, partial remission; BEAC/M, BCNU 300 day-7, and etoposide 1,600, cytarabine 800, cyclophosphamide 1,500, day Ϫ6,Ϫ5,Ϫ4,Ϫ3, or melphalan 140, day -2; MLF, melphalan 200, day-4,Ϫ3; TBI-Cy, total body irradiation 12 Gy in 4 fractions, day-7,Ϫ6,Ϫ5,Ϫ4, and cyclophosphamide 120 mg/kg, day -3,Ϫ2.
transplantation, engraftment failure rate, time to neutrophil and platelet engraftment, number of RBC and platelet transfusions, and survival were similar in both groups (Table 3 ). The median time to discharge the patient to the outpatient unit was 14 days (range, 5 to 27 days) in the at-home group compared with 15 days (range, 13 to 31 days) in the in-hospital group (P ϭ NS).
Fever, Days Receiving Antibiotics, and Infections
Thirty-eight patients (76%) experienced body temperature of 38°C or higher in the at-home group compared with 48 patients (96%) in the in-hospital group (P ϭ .008). Median day of appearance of fever was day ϩ4 (range, day ϩ2 to ϩ13) in the at-home group and day ϩ3.5 (range, ϩ1 to ϩ12) in the control group (P ϭ NS; Table 3 ). Patients with fever received IV antibiotics for a median of 8 days (range, 5 to 16 days) in the at-home group and 9 days (range, 6 to 24 days) in the in-hospital group (P ϭ NS). Moreover, glycopeptide and/or amikacin was added in 26 (68%) of the 38 febrile episodes in the at-home group compared with 31 (65%) of the 48 in the inhospital group (P ϭ NS). Empirical use of amphotericin B was 0% in the at-home group versus 10% in the in-hospital group (P ϭ NS). Duration of the fever was significantly shorter in the at-home group, with a median of 2 days (range, 1 to 11 days) versus 5 days (range, 1 to 20 days), respectively (P ϭ .00003). No single patient of both groups presented a new febrile episode after resolution of the first episode. No significant difference was observed in the incidence of bacteremia between the two groups (Table 3) . Bacterial infection was documented in 10 (26%) of 38 febrile episodes in the at-home group compared with 14 (29%) of 48 in the hospital group. Coagulase-negative Staphylococci was the more frequent bacteria isolated in both groups (80% and 78%, respectively). The other infectious agents were Pseudomonas aeruginosa (n ϭ 1) and Streptococcus viridans (n ϭ 1) in the at-home group; and Candida inconspicua (n ϭ 1), Streptococcus mitis (n ϭ 1) and Enterococcus faecalis (n ϭ 1) in the in-hospital group.
Other Complications
No significant difference was observed in the incidence of WHO mucositis grades 2 to 3 between the two groups (24% v 34%, respectively). No single patient experienced WHO mucositis grade 4, and no patient required total parenteral nutrition. There was no significant difference in the incidence of WHO diarrhea grade 2 to 3 (35% v 39%, respectively). None of the patients in either group died as a result of the procedure.
Day Care Unit Consultations and Readmissions
At-home patients visited the hospital during the aplasia period for transfusion support, fever, or due to other complications, with a median of 3 (range, one to nine) visits per patient. In 40% of these visits a physician intervention was required due to fever (75%), central venous catheter-related complications (10%), and other reasons (15%), including mucositis, bleeding, diarrhea or chemotherapy related exanthema.
In the at-home group, readmission to the aplasia period was necessary in four patients (8%), due to pneumonia (n ϭ 1) and fever with hemodynamic instability (n ϭ 3). Time to readmission was on days ϩ3, ϩ4, ϩ6 and ϩ10, respectively, and the total number of hospitalization days was 26. The median number of days in the inpatient area for the 50 patients in the at-home ASCT group was 8 days (range, 0 to 18 days), as compared with 25 days (range, 18 to 49 days) for patients in the in-hospital group (P Ͻ .00001). Thus, at-home management of the aplasia phase after ASCT was associated with a reduction of 18.6 hospitalization days per patient.
Quality of Life
Thirty patients and their caregivers were invited to complete an anonymous questionnaire after the whole procedure was completed. All patients and caregivers felt safe at home. Twenty-nine patients (95%) indicated that they would choose again to receive at-home ASCT and that they would recommend the procedure to a fellow patient. Primary advantages mentioned were the quiet and increased home comfort (n ϭ 20), the familiar environment (n ϭ 8), the free choice of activity (n ϭ 8), the free choice of food (n ϭ 6), and increased privacy (n ϭ 4). On the other hand, 10 patients reported some disadvantages like the anxiety and fatigue (n ϭ 6), the cost of local hotel or apartment (n ϭ 2), and the anxiety of the caregiver (n ϭ 2).
Total Medical Charges
As shown in Table 4 , total median charges were approximately half in at-home group as compared with in-hospital group (3,345 € v 6,250 €, respectively; P Ͻ .00001). At-home savings resulted mainly from lower charges on hospitalization, pharmacy, laboratory, and physician fees. In contrast, there was a trend for a higher cost in at-home group for nurse fees. No significant difference was observed in the charges related to transfusions between the two groups.
DISCUSSION
In this prospective series of patients receiving at-home ASCT we have observed a lower incidence of episodes of febrile neutropenia and shorter duration of fever than in a well-matched control group of patients who underwent ASCT at the hospital. Interestingly, the need for hospitalization was much lower than that reported in previous series of at-home ASCT. [7] [8] [9] [10] [11] [12] [13] [14] [15] Three factors might explain these results: a highly experienced team, the prophylactic administration of ceftriaxone, and the treatment of febrile neutropenia with piperacillin and tazobactam using a portable intermittent infusion pump.
Infection is one of the most common and severe complications after hematopoietic transplantation. Chemoprophylaxis with fluoroquinolones has reduced the incidence of Gram-negative bacteremia, including those caused by Pseudomonas aeruginosa, but has increased the incidence of quinolone-resistant aerobic Gram-negative bacilli infections and Gram-positive infections, in particular those caused by Staphylococcus spp and Streptococcus spp. 26 Moreover, despite prophylaxis with oral antibiotics most of the patients who receive myeloablative hematopoietic transplantation will develop fever. 27 This observation has led some investigators to study the effectiveness of the administration of prophylactic intravenous antibiotic after hematopoietic transplantation. Preliminary reports suggest that this approach could be effective in preventing early bacterial infections and related complications after hematopoietic transplantation and to be cost effective. [28] [29] [30] Ceftriaxone is a third-generation cephalosporin with a long elimination half-life, effective against a broad range of Gram-positive and Gram-negative bacteria but having a limited activity against Pseudomonas aeruginosa. 31, 32 This antibiotic is suitable for once-daily intravenous administration and facilitates patient management on an outpatient basis. Of note, whereas data on the safety and efficacy of ceftriaxone in the treatment of febrile neutropenia in low-risk patients are available, 31, 32 no previous studies have addressed the role of prophylactic intravenous ceftriaxone in high-risk neutropenic patients. This study indicates that prophylaxis with ceftriaxone reduces the incidence of febrile neutropenia in at-home ASCT patients. Thus, patients in the at-home ASCT group, as compared with those in the in-hospital group receiving only quinolone prophylaxis, had a lower rate febrile neutropenia (76% v 96%; P ϭ .008).
Empirical first-line antibacterial treatment of febrile neutropenia of at-home ASCT has not been sufficiently studied. For this reason, the most appropriate antibiotic strategy has not been yet defined.
33, 34 We administered piperacillin and tazobactam IV using a portable intermittent infusion pump in the at-home group because this antibiotic has shown stability for at least 24 hours at 37°C. 6 Use of carbapenem for empirical first-line antibacterial treatment is an alternative to piperacillin and tazobactam, but we discarded it because this antibiotic becomes unstable after more than 3 hours at 37°C. Piperacillin and tazobactam administration as an at-home treatment of febrile neutropenia proven to be effective and safe. Thus, it was associated with a significant reduction in the number of fever days in the at-home ASCT group with respect to the in-hospital ASCT group, which received imipenem. Moreover, management of the intermittent pump, which automatically delivers the required dose of antibiotic each 8 hours without nurse intervention, was not associated with a higher incidence of infection by Staphylococcus spp or to local complications.
In our study, both the lower febrile neutropenia and the successful control of fever at-home resulted in an overall readmission rate significantly lower (8% v 20% to 72%, respectively) than that observed in previous at-home ASCT series (Table 5) . [7] [8] [9] [10] [11] [12] [13] [14] [15] In all these studies, the 
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At-home: store material, telephone, and car; in-hospital: auxiliary workers fees (3 hours/day), subsistence, and store material. †At-home: 45 minutes/visit and 50 minutes/week for discussing with the nurse patient's condition; in-hospital: 30 minutes/visit, seven visits/week. ‡At-home: 4 hours/day (direct visit and travel time); in-hospital: 3 hours/day (direct visit). §At-home: three hematology and two chemistry assessments/week, respectively; in-hospital: seven hematology and three chemistry assessments/week.
conditioning was delivered at the hospital and the aplasia period was followed at home, and the criteria for rehospitalization were similar to those of our series. The hospitalization rate was significantly higher than in the present series in all of them but in the study by Jagannath et al 10 that included only patients diagnosed with multiple myeloma conditioned with melphalan and, hence, of low-risk related complications. The rehospitalization rate resulted in a savings of 18.6 hospital bed days per patient with respect to the in-hospital control group. This fact significantly reduced the cost of ASCT (Table 4) , which may be of particular interest for ASCT programs in developing countries. 35 In a previous report, Summers et al 18 compared the psychosocial impact of at-home versus in-hospital ASCT, finding that the first group had significantly higher scores for emotional well-being and global quality of life. In agreement with these findings, patients and caregivers in our study were largely very positive about the program.
In conclusion, we report a strategy of at-home ASCT that, in comparison with in-hospital ASCT, is associated with fewer episodes of fever, lower duration of febrile neutropenia, low rate of rehospitalization, and a drastic reduction in the cost and of the need for hospital beds.
